CEO Matt Davidson Buys 232k Shares as ADIAL Rebrands to Azora Therapeutics
Azora Therapeutics’ CEO buys 232k shares amid rebrand, new ulcerative colitis trial, and private placement—insider confidence signals potential upside despite current volatility.
4 minutes to read